CytoSorbents Q3 revenue rises on growth in distributor and partner sales

Cytosorbents

12/11/2026 22:29

Overview
US blood purification firm's Q3 revenue rose 3% yr/yr, led by distributor and partner sales
Company achieved operating cash flow breakeven, reflecting cost cuts and higher gross margin
Adjusted EBITDA loss improved by 86% yr/yr

Outlook
Company aims to sustain operating cash flow at or near breakeven while investing to accelerate sales growth
CytoSorbents prioritizes restoring growth in Germany and expanding international sales
Company expects to submit new De Novo application for DrugSorb-ATR to FDA in early 2027

Result Drivers
MANUFACTURING EFFICIENCIES - Manufacturing efficiencies and improved sourcing expanded product gross margin to 75%
DISTRIBUTOR SALES GROWTH - Distributor and strategic partner sales rose 16% yr/yr
COST REDUCTIONS - Operating expenses fell 11% due to lower headcount and expense management

Company press release: ID:nPn2WRQL4a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$9.73 mln
$9.91 mln (2 Analysts)
Q3 Loss Per Share
 
$0.58
 
Q3 Gross Margin
 
75%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Cytosorbents Corp is $15.00, about 180.9% above its November 11 closing price of $5.34

Reuters Recommended Reads
Nov 12 - NeuroPace Q3 revenue misses analyst estimates, dragged by account-level issues
Nov 12 - Sanara MedTech Q3 revenue misses estimates on soft tissue product sales
Nov 10 - Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)